

Muhammad Furqan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8682844/publications.pdf>

Version: 2024-02-01

30
papers

1,571
citations

623734

14
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

2977
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biology, 2022, 53, 102318.	9.0	8
2	Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy. Redox Biology, 2021, 38, 101804.	9.0	14
3	Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer, 2021, 21, 808.	2.6	43
4	Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation. Translational Lung Cancer Research, 2021, 10, 3608-3615.	2.8	5
5	Time to put it out â€“ nurse-facilitated tobacco treatment in a comprehensive cancer center. Translational Behavioral Medicine, 2021, 11, 1726-1738.	2.4	0
6	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	2.8	12
7	Narrative review: mesenchymal-epithelial transition inhibitorsâ€™ meeting their target. Translational Lung Cancer Research, 2021, 10, 462-474.	2.8	6
8	The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Critical Reviews in Oncology/Hematology, 2019, 143, 148-152.	4.4	60
9	Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). Cancer Medicine, 2019, 8, 2730-2739.	2.8	9
10	Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors. Journal of Thoracic Oncology, 2019, 14, e77-e78.	1.1	14
11	Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. Journal of Thoracic Disease, 2018, 10, 5850-5859.	1.4	17
12	Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials. Anticancer Research, 2018, 38, 5247-5251.	1.1	0
13	Atezolizumab after Nivolumab-Induced Inflammatory Polyarthriti: Can Antiâ€“PD-L1 Immunotherapy Be Administered after Antiâ€“PD-1â€“Related Immune Toxicities?. Journal of Thoracic Oncology, 2018, 13, e102-e103.	1.1	11
14	O ₂ â€“...â€” and H ₂ O ₂ -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell, 2017, 31, 487-500.e8.	16.8	316
15	Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. Cancer Research, 2017, 77, 5054-5067.	0.9	31
16	A Single-Institution Analysis of Thymic Carcinoma Treated with Multi-Modality Therapy. , 2017, 1, .		0
17	The Conundrum of â€œWarfarin Hypersensitivityâ€• American Journal of Therapeutics, 2016, 23, e911-e915.	0.9	4
18	Air leakage in multiple compartments after endoscopy. Cleveland Clinic Journal of Medicine, 2016, 83, 705-707.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Novel ALK inhibitors in clinical use and development. Journal of Hematology and Oncology, 2015, 8, 17.	17.0	81
20	Germline mutations predisposing to non-small cell lung cancer. Familial Cancer, 2015, 14, 463-469.	1.9	15
21	Novel agents for advanced pancreatic cancer. Oncotarget, 2015, 6, 39521-39537.	1.8	29
22	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. Frontiers of Medicine, 2014, 8, 254-258.	3.4	0
23	Ibrutinib and Indolent B-Cell Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 253-260.	0.4	14
24	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of Hematology and Oncology, 2013, 6, 88.	17.0	211
25	STAT inhibitors for cancer therapy. Journal of Hematology and Oncology, 2013, 6, 90.	17.0	157
26	Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Research, 2013, 1, 5.	6.8	146
27	MEK and the inhibitors: from bench to bedside. Journal of Hematology and Oncology, 2013, 6, 27.	17.0	219
28	APACHE II scores as predictors of cardio pulmonary resuscitation outcome: Evidence from a tertiary care institute in a low-income country. Saudi Journal of Anaesthesia, 2012, 6, 31.	0.7	8
29	Miliary Pattern on Chest Radiography: TB or not TB?. Mayo Clinic Proceedings, 2010, 85, 108.	3.0	13
30	Cardiopulmonary resuscitation: outcome and its predictors among hospitalized adult patients in Pakistan. International Journal of Emergency Medicine, 2008, 1, 27-34.	1.6	20